Several gene therapies are or will soon be in late-stage human trials. One of them could be the first to get FDA approval for sale in the U.S.
Susan YoungFollow @twitterapi
I’m the biomedicine editor for MIT Technology Review. I look for stories where technology stands to improve human health or advance our understanding of the human condition.
I joined MIT Technology Review in March 2012 after a brief stint in the Washington, D.C., news bureau of the scientific journal Nature. Before I ventured to the East Coast, I spent several years in the San Francisco Bay Area as a doctoral student in molecular biology and one whirlwind year in science-writing boot camp in Santa Cruz.
In California, I wrote for the Stanford University press offices, the Multiple Sclerosis Discovery Forum, and the Salinas Californian newspaper. I grew up in a small town in eastern Texas, surrounded by bird song, rolling cattle fields, and lanky pine trees. When I’m not exploring health tech, you will probably find me cooking or giggling over an exceptional LOLcat.
Susan Young's Stories
An upcoming film, The Perfect 46, is about a fictional genomics company with a not-so-fictional idea.
Despite promising results in controlling neuronal activity, leaders in brain research still wrestle over turning their work into treatments.
Notre Dame researchers will test a concussion-detection app on nearly a thousand high school and youth football players.
Researchers are using smart helmets and imaging to study brain injury risk in young football players over a season.
By studying the interactions between our bodies and our microbes, a startup hopes to find new ways of treating disease.
Nektar Therapeutics is developing a painkiller that may enter the brain too slowly to be abused.
Researchers have grown brain tissue with distinct regions that mimic different functional structures of the developing brain.
A real-time MRI system can help surgeons perform faster and safer brain operations.
Researchers show off flashing fish brains and the technology behind them.